Amarin (AMRN) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vanda Pharmaceuticals (VNDA) has outperformed Amarin (AMRN) over the past year, losing 17.0% versus a loss of 37.8%. Over five years, VNDA leads with a -75.4% price change compared with -88.4% for AMRN. Vanda Pharmaceuticals is the larger company by market cap ($273.9 million vs $253.3 million), about 1.1 times the size.
On valuation, Amarin trades at a lower forward P/E (12.2x vs 22.7x for Vanda Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | VNDA |
|---|---|---|
| Share price | $11.99 | $4.53 |
| Market cap | $253.26M | $273.90M |
| 1-day change | -0.25% | -0.66% |
| YTD return | -14.11% | -48.64% |
| 1-year return | -37.81% | -17.03% |
| 5-year return | -88.38% | -75.39% |
| Forward P/E | 12.23 | 22.65 |
| EPS (TTM) | $-1.20 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.90 | $9.94 |
| 52-week low | $11.83 | $4.27 |
| Distance from 52-week high | -42.63% | -54.43% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +4.25% | +159.38% |
| Average volume | 66.23K | 974.13K |
| Shares outstanding | 21.12M | 60.46M |
| Employees | 80 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VNDA has outperformed AMRN by 20.8 percentage points over the past year.
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
AMRN vs VNDA FAQ
Which is bigger, Amarin or Vanda Pharmaceuticals?
Vanda Pharmaceuticals (VNDA) is larger, with a market capitalization of $273.90M compared with $253.26M for Amarin (AMRN).
Which stock has performed better over the past year, AMRN or VNDA?
VNDA returned -17.03% over the past 12 months, compared with -37.81% for AMRN (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and Vanda Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.